Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences

被引：32
|
作者：
Johnson, Stuart [1 ,2 ]
Gerding, Dale N. [1 ,2 ]
机构：
[1] Hines Vet Affairs Hosp, Chicago, IL USA
[2] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA
来源：
CLINICAL INFECTIOUS DISEASES | 2013年 / 56卷 / 02期
关键词：
D O I：
10.1093/cid/cis833
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：309 / U167
页数：2
相关论文
共 50 条
  • [21] A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin
    Abrar K. Thabit
    M. Jahangir Alam
    Mohammed Khaleduzzaman
    Kevin W. Garey
    David P. Nicolau
    Annals of Clinical Microbiology and Antimicrobials, 15
  • [22] Clostridium-difficile-Infection - an underestimated Threat: Fidaxomicin prevent Recurrences and saves Costs
    Funck, Monika
    VISCERAL MEDICINE, 2016, 32 (01) : 67 - 67
  • [23] The economic effectiveness of fidaxomicin over vancomycin in treating clostridium difficile infection in cancer patients: A systematic review
    Abughanimeh, Omar Khaled Mahmoud
    Al Momani, Laith
    Morgan, Tyler
    Abu Ghanimeh, Mouhanna
    Pluard, Timothy J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Factors Influencing Time to Resolution of Diarrhea in Patients with Clostridium difficile Infection Treated with Fidaxomicin or Vancomycin.
    Gerding, D.
    Crook, D.
    Miller, M.
    Louie, T.
    Cornely, O.
    Peto, T.
    Gorbach, S.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 : S144 - S145
  • [25] A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin
    Thabit, Abrar K.
    Alam, M. Jahangir
    Khaleduzzaman, Mohammed
    Garey, Kevin W.
    Nicolau, David P.
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2016, 15
  • [26] Safety and Efficacy of Fidaxomicin in Patients With Clostridium Difficile Infection
    Donnelley, Monica A.
    Duby, Jeremiah J.
    Cocanour, Christine S.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2013, 5 : 75 - 79
  • [27] Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients
    Martin Rizo, Lara
    Malpartida Flores, Maria
    Fernandez Lison, Luis Carlos
    MEDICINA CLINICA, 2019, 153 (07): : 298 - 299
  • [28] Clostridium difficile in 7 European countries and North America: Fidaxomicin vs vancomycin therapy
    Crook, D.
    Cornely, O.
    Esposito, R.
    Poirier, A.
    Somero, M.
    Weiss, K.
    Tillotson, G.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2012, 16 : E242 - E242
  • [29] Predictors for Treatment Failure With Fidaxomicin (FDX) and Vancomycin (VAN) in Clostridium difficile Infection (CDI)
    Louie, Thomas J.
    Golan, Yoav
    Mullane, Kathleen M.
    Miller, Mark
    Crook, Derrick W.
    Lentnek, Arnold
    Kean, Yin
    Gorbach, Sherwood L.
    GASTROENTEROLOGY, 2012, 142 (05) : S739 - S739
  • [30] Rifaximin chaser following standard therapeutic cocktail for breaking the cycle of multiple C. difficile diarrhea recurrences
    Johnson, Stuart
    Galang, Minerva
    Schriever, Christopher
    Kelly, Ciaran
    Gerding, Dale
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S219 - S220
12345